Physician profile
Peter Weiss
NPI 1770682593
$5,884.94
in general payments reported to CMS, 2019-2025
36 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $2,790 · 2021: $567 · 2022: $655 · 2023: $482 · 2024: $401 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $2,600.14 | 2019-2023 | Acessa Provu System |
| Abbvie INC. | $715.42 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Abbott Laboratories | $390.96 | 2022-2025 | Ensite, Ensite Precision |
| Bayer Healthcare Pharmaceuticals INC. | $234.80 | 2019-2024 | |
| Caldera Medical, INC | $174.05 | 2019 | |
| Coopersurgical, INC. | $164.69 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Biohaven Pharmaceutical Holding Company LTD. | $151.48 | 2022 | |
| Boston Scientific Corporation | $136.26 | 2021 | |
| Allergan, INC. | $130.54 | 2019-2020 | |
| Therapeuticsmd, INC. | $127.20 | 2019-2022 | |
| Astellas Pharma US INC | $117.71 | 2023-2024 | Veozah |
| Sumitomo Pharma America, INC. | $78.03 | 2023-2024 | Myfembree |
| Evofem Biosciences, INC. | $71.36 | 2020-2023 | Phexxi |
| Merck Sharp & Dohme LLC | $66.70 | 2019-2020 | |
| Agile Therapeutics, INC. | $66.41 | 2023-2024 | Twirla |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $63.42 | 2022-2024 | |
| Exact Sciences Corporation | $62.73 | 2023-2024 | Cologuard Collection Kit |
| Exeltis, USA INC. | $46.29 | 2022-2024 | Slynd |
| Ascend Therapeutics US, LLC | $45.28 | 2021-2022 | |
| Novo Nordisk INC | $45.27 | 2019-2023 | Wegovy |
| Shield Therapeutics INC | $44.62 | 2022 | |
| Myovant Sciences INC. | $43.50 | 2021-2022 | |
| Lupin INC. | $32.97 | 2019-2020 | |
| Bridgebio Pharma, INC. | $32.23 | 2025 | Attruby |
| Lilly USA, LLC | $29.86 | 2024 | Zepbound |
| Pfizer INC. | $28.45 | 2023 | |
| Medicem INC. | $23.25 | 2020 | |
| Channel Medsystems, INC. | $21.22 | 2021 | |
| Organon LLC | $21.16 | 2021 | |
| Daiichi Sankyo INC. | $20.46 | 2019 | |
| Hikma Pharmaceuticals USA | $20.28 | 2019 | |
| Avion Pharmaceuticals | $17.82 | 2023 | Balcoltra |
| Scynexis, INC. | $17.06 | 2022 | |
| Becton, Dickinson and Company | $16.46 | 2022 | |
| Dysis Medical, INC. | $13.48 | 2020 | |
| Mission Pharmacal Company | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.